# Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine

> **NCT05993975** · PHASE4 · COMPLETED · sponsor: **Sindh Institute of Urology and Transplantation** · enrollment: 108 (actual)

## Conditions studied

- Post Operative Pain

## Interventions

- **DRUG:** Bupivacain 0.5%
- **DRUG:** Dexmedetomidine Hydrochloride

## Key facts

- **NCT ID:** NCT05993975
- **Lead sponsor:** Sindh Institute of Urology and Transplantation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-20
- **Primary completion:** 2022-02-18
- **Final completion:** 2022-02-18
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2023-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05993975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05993975, "Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05993975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*